Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.
Nina Chavez, MBA, FACMPE, chief operating officer, New Mexico Oncology Hematology Consultants, Ltd., explains how expensive therapies like chimeric antigen receptor (CAR) T-cell therapy are creating reimbursement challenges.
Transcript
With therapies like CAR T-cell therapy entering the market, will reimbursement present significant challenges to providers?
CAR T—I was talking to my doctor about this because I’m not clinical and I want to make sure I got her opinion, and she said, with CAR T, the insurers are not paying for it right now, we don’t know what’s going to happen, it really should be happening in a hospital, but if you’re not partnering with your hospital and you’re trying to do it in an independent practice, it’s not going to be easy.
I think from a cost perspective, we don’t know what the market’s going to do, we don’t know what the payers are going to do. We do know that we can’t get that medication, we can’t get CAR T therapies very easily in community oncology. We can’t even get it from the [group purchasing organization] we currently have. You have to go through a certain specialty, and it is very costly. So, I think that’s remaining to be seen. It’s something that we’ll have to kind of see how it goes.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More